Sobi Presents New Haemophilia Data at ISTH 2026, Highlighting Portfolio Strength
Event summary
- Sobi will present new data across its haemophilia portfolio at ISTH 2026, including analyses of Altuvoct®, Elocta®, and Alprolix®.
- Presentations cover joint health outcomes, bleeding outcomes, perioperative management, and real-world treatment experiences.
- Key studies include interim results from the FREEDOM study on Altuvoct® and final surgery data from the B-MORE study on Alprolix®.
- ISTH 2026 Congress takes place in Paris from July 11–15, 2026.
The big picture
Sobi's presentation of new haemophilia data at ISTH 2026 underscores its commitment to advancing care through clinical development and real-world evidence. The focus on joint health, bleeding outcomes, and perioperative management aligns with broader industry trends toward personalized and long-term treatment solutions for rare diseases. With a collaboration in place with Sanofi, Sobi is well-positioned to expand its market reach and solidify its leadership in haemophilia therapies.
What we're watching
- Clinical Efficacy
- How the interim results from the FREEDOM study will impact the adoption of Altuvoct® in severe haemophilia A.
- Market Positioning
- Whether Sobi can leverage real-world evidence to strengthen its portfolio against competitors in the haemophilia space.
- Regulatory Dynamics
- The pace at which new data could influence regulatory approvals or label expansions for Altuvoct® and other products.